π¬ GLP-1 and GIP/GLP-1 Receptor Agonists in Obesity & Type 2 Diabetes (2025 Update)
By Dr. Sk Sabir Rahaman, MBBS , MD (Pharmacology), DFM(Family Medicine), FCFM, CCEBDM, CCLSD π Specialist Family Physician | Consultant Pharmacologist | Lifestyle & Diabetes Expert Understanding Semaglutide, Tirzepatide, and the Debate About Weight Regain π§ 1. Why Everyone’s Talking About These Drugs In just a few years, GLP-1 receptor agonists (like semaglutide ) and the newer dual GIP/GLP-1 agonist ( tirzepatide ) have reshaped how we treat obesity and type 2 diabetes (T2DM) . They do much more than lower blood sugar — they suppress appetite , slow digestion , and help the body use insulin more efficiently. The result: major, sustained weight loss and better metabolic health while on treatment. Semaglutide 2.4 mg : typically 10–15% average body weight loss in trials. Tirzepatide : often 15–20% or more — the highest seen in modern studies. SELECT trial: proved semaglutide even reduces heart attacks and strokes in obese people without diabetes . ⚙️ 2...